The mutational spectrum of fibroblast growth factor receptor 3 (FGFR3) in individuals with achondroplasia. In humans, the mutations associated with achondroplasia patients are mainly located in ...
If approved, Ascendis’ TransCon CNP would become the second therapy for achondroplasia, challenging BioMarin’s Voxzogo.
CARLSBAD, Calif., Aug. 21, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target ...
- In Cohort 5 of PROPEL 2 (0.25 mg/kg/day), oral treatment with infigratinib resulted in a statistically significant and sustained increase in annualized height velocity (AHV), with a mean change from ...
CARLSBAD, Calif., Oct. 28, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large ...
CARLSBAD, Calif., Aug. 1, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large ...
- BridgeBio completed an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), and a scientific advice engagement with the European Union (EU) European Medicines Agency (EMA) - FDA ...
COPENHAGEN, Denmark, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency ...
The achondroplasia market size shall grow during the forecast period (2023–2032) due to the launch of upcoming therapies and the increasing cases of achondroplasia. This achondroplasia market is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback